领先的3D打印机OEM 3D Systems宣布与比利时生物技术公司Antleron建立合作关系，以开发用于个性化患者护理的再生产品。
Leading 3D printer OEM 3D Systems has announced a partnership with Antleron, a Belgium-based biotechnology company, to develop regenerative products for personalized patient care.
“ Antleron的愿景是可持续地将活疗法引入诊所，” Antleron首席执行官Jan Schrooten说。 “ 3D打印是这项工作的关键，我们渴望与3D Systems及其专家合作。
“The vision of Antleron is to sustainably bring living therapies into the clinic,” said Jan Schrooten, CEO of Antleron. “3D printing is key to this endeavor, and we are eager to collaborate with 3D Systems and its experts.
“我期待着开创性的解决方案，我们将能够提高生物印制的效率扩展其生物医学应用范围。”
“I LOOK FORWARD TO THE PIONEERING SOLUTIONS WE’LL BE ABLE TO ACHIEVE TO ELEVATE THE EFFICACY OF BIOPRINTING AND EXTEND ITS BIOMEDICAL APPLICATION REACH.”
生活疗法工厂
Living therapy factories
Antleron成立于2014年，其开发的软件引领了实现个性化医学的工作流程。解决方案之一是“活体疗法工厂”，它将细胞、生物材料、生物制剂、生物反应器和3D Systems打印机合并在一起，以加快生命疗法的工程设计。它使用系统的设计质量（QbD）来开发药物和AI。
Founded in 2014, Antleron has developed software which pioneers workflows enabling personalized medicine. One of its solutions, ‘living therapy factory’ merges cells, biomaterials, biologics, bioreactors, and 3D Systems printers to accelerate the engineering of living therapies. This operates using systematic quality-by-design(QbD) an approach to developing pharmaceuticals and AI.
3D Systems和Antleron将解决医疗设备和先进治疗药物（ATMP）应用的解决方案。尤其是，不断增长的细胞和组织的发展将成为实现从静态2D过渡到基于生物反应器的3D细胞培养的焦点。这将为生产医疗植入物、疫苗、细胞疗法和活组织的方法开辟新途径。
Through the new partnership, 3D Systems and Antleron will address solutions for medical device and advanced therapy medicinal product (ATMP) applications. In particular, the advancement of growing cells and tissues will be a focus to enable the transition from a static 2D to a bioreactor-based 3D cell culture. This will lead to new ways to methods of producing medical implants, vaccines, cell therapies, and living tissues.
ProJet MJP 2500和 3D打印机以及3D Systems的VisiJet材料等技术将用于建立灵活的可扩展的数字工厂，以构建新的3D生物打印平台。 模块化封闭式参数系统包括数字监控和质量控制。
Technologies such as ProJet MJP 2500 and Figure 4 3D printers as well as VisiJet materials from 3D Systems will be utilized to establish a flexible, scalable digital factory approach in building new 3D bioprinting platforms. The modular closed parametric systems includes digital monitoring and quality control for risk mitigation.
A ProJet MJP 2500
3D Systems和医疗保健
3D Systems and healthcare
3D Systems在医疗保健领域采取了其他措施。最近，该公司为其VSP骨科平台获得了美国食品药品监督管理局（FDA）的510（k）许可。 该公司还与美国联合疗法公司（United Therapeutics Corporation）签订了现有3D生物打印协议，两家合作伙伴正在努力开发用于肺部的再生疗法。
3D Systems has made several other moves into the healthcare sector. Most recently, the company attained 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its VSP Orthopaedics platform. The company also has an existing 3D bioprinting agreement with United Therapeutics Corporation in which the two partners are working to develop regenerative treatments for the lungs.
在公司最新的合作伙伴关系中，3D Systems联合创始人兼CTO Chuck Hull补充说：“ 3D Systems很高兴与Antleron合作探索生物打印，尤其是他们利用3D Systems开发端到端解决方案的能力完全是 “最先进的印刷平台和材料。”
Upon the company’s latest partnership, Chuck Hull, co-founder and CTO, 3D Systems, added, “3D Systems is excited about working with Antleron as they explore bioprinting, and especially their capacity to develop end-to-end solutions utilizing the 3D Systems’ state of the art printing platforms and materials.”
“展望未来，生物打印和再生医学是3D打印的巨大机遇，我们期待扩大3D Systems在这些激动人心的领域中的作用。”
“As we look to the future, bioprinting and regenerative medicine are large opportunities for 3D printing, and we look forward to expanding the role 3D Systems will play in these exciting fields.”
该协议的开发成果将于11月19日至22日在Formnext 2019上3D Systems展台D3的12.1展厅展出。
Developments on this agreement will be exhibited at Formnext 2019 from November 19-22, at 3D Systems’ booth D03, Hall 12.1.
3D Systems FDA清除的VSP Orthopedics解决方案使外科医生能够在进入手术室之前获得患者解剖结构的清晰3D可视化图像并制定个性化的手术计划。
3D Systems’ FDA cleared VSP Orthopaedics solution enables surgeons to obtain a clear 3D visualization of a patient’s anatomy and develop a personalized surgical plan, prior to entering the operating room. Image via 3D Systems。
